和誉在港交所公告,公司之附属公司和誉医药宣布,与阿斯利康签署战略合作协议,共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.